VBIV vs. NRBO, COCP, HUGE, NERV, AYTU, VAXX, TNXP, ORGS, TLPH, and AVTX
Should you be buying VBI Vaccines stock or one of its competitors? The main competitors of VBI Vaccines include NeuroBo Pharmaceuticals (NRBO), Cocrystal Pharma (COCP), FSD Pharma (HUGE), Minerva Neurosciences (NERV), Aytu BioPharma (AYTU), Vaxxinity (VAXX), Tonix Pharmaceuticals (TNXP), Orgenesis (ORGS), Talphera (TLPH), and Avalo Therapeutics (AVTX). These companies are all part of the "pharmaceutical preparations" industry.
NeuroBo Pharmaceuticals (NASDAQ:NRBO) and VBI Vaccines (NASDAQ:VBIV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation, earnings and community ranking.
NeuroBo Pharmaceuticals has a beta of -0.23, suggesting that its share price is 123% less volatile than the S&P 500. Comparatively, VBI Vaccines has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500.
NeuroBo Pharmaceuticals has higher earnings, but lower revenue than VBI Vaccines.
VBI Vaccines received 473 more outperform votes than NeuroBo Pharmaceuticals when rated by MarketBeat users. However, 75.00% of users gave NeuroBo Pharmaceuticals an outperform vote while only 74.74% of users gave VBI Vaccines an outperform vote.
In the previous week, NeuroBo Pharmaceuticals and NeuroBo Pharmaceuticals both had 1 articles in the media. VBI Vaccines' average media sentiment score of 0.00 equaled NeuroBo Pharmaceuticals'average media sentiment score.
NeuroBo Pharmaceuticals presently has a consensus target price of $10.00, suggesting a potential upside of 154.45%. Given VBI Vaccines' higher probable upside, equities research analysts plainly believe NeuroBo Pharmaceuticals is more favorable than VBI Vaccines.
NeuroBo Pharmaceuticals has a net margin of 0.00% compared to NeuroBo Pharmaceuticals' net margin of -1,069.29%. VBI Vaccines' return on equity of -59.42% beat NeuroBo Pharmaceuticals' return on equity.
1.4% of NeuroBo Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.3% of VBI Vaccines shares are owned by institutional investors. 0.5% of NeuroBo Pharmaceuticals shares are owned by company insiders. Comparatively, 10.4% of VBI Vaccines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
NeuroBo Pharmaceuticals beats VBI Vaccines on 7 of the 12 factors compared between the two stocks.
Get VBI Vaccines News Delivered to You Automatically
Sign up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VBIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VBI Vaccines Competitors List
Related Companies and Tools
